Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortization of Deferred Charges (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Amortization of Deferred Charges for 3 consecutive years, with -$1.2 million as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges fell 342.96% to -$1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.7 million through Dec 2025, down 1.33% year-over-year, with the annual reading at -$1.7 million for FY2025, 1.33% down from the prior year.
  • Amortization of Deferred Charges hit -$1.2 million in Q4 2025 for Compass Therapeutics, down from -$375000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $26000.0 in Q1 2025 to a low of -$1.2 million in Q4 2025.
  • Historically, Amortization of Deferred Charges has averaged -$545833.3 across 3 years, with a median of -$484500.0 in 2023.
  • Biggest YoY gain for Amortization of Deferred Charges was 106.91% in 2025; the steepest drop was 342.96% in 2025.
  • Year by year, Amortization of Deferred Charges stood at -$812000.0 in 2023, then skyrocketed by 66.75% to -$270000.0 in 2024, then plummeted by 342.96% to -$1.2 million in 2025.
  • Business Quant data shows Amortization of Deferred Charges for CMPX at -$1.2 million in Q4 2025, -$375000.0 in Q3 2025, and -$128000.0 in Q2 2025.